Cardiovascular Outcome clinical trials

Explore recruiting cardiovascular outcome clinical trials.

Recruiting cardiovascular outcome studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cardiovascular Outcome trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

SGLT2 INHIBITION (DAPAGLIFLOZIN) IN DIABETIC AND NON-DIABETIC HEMODIALYSIS PATIENTS WITH AND WITHOUT RESIDUAL URINE VOLUME: A PROSPECTIVE RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PHASE II TRIAL

Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects with End Stage Kidney Disease Undergoing Dialysis

Hungary, Germany, Sweden, Belgium, Austria, Bulgaria +16 more

Phase II and Phase III (Integrated) EU CTIS Study details

Early treatment of Atrial fibrillation for Stroke prevention Trial in acute STROKE (EAST-STROKE)

Spain, Germany, Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

A phase II, multicenter, 1:1 randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy of bolus application of Cyclosporine A (CsA) or Placebo in patients with Takotsubo syndrome. (Cyclosporine In Takotsubo syndrome (CIT))

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

(21466) A multicenter, randomized, double-blind, placebo-controlled, Phase 3 study to investigate the efficacy, safety, and PK/ PD of finerenone, in addition to standard-of-care, in pediatric patients, 6 months to < 18 years of age, with heart failure (HF) and left ventricular systolic dysfunction (LVSD)

Czechia, Poland, Portugal, Austria, Finland, Greece +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Discontinuation or Continuation of SGLT-2 Inhibitors Before Cardiac Surgery: Impact on Postoperative Cardiovascular Outcomes – DISCO Study

France

Therapeutic use (Phase IV) EU CTIS Study details

Cardiovascular Outcome trials by city

Cardiovascular Outcome in Toronto Cardiovascular Outcome in Vancouver Cardiovascular Outcome in Montreal Cardiovascular Outcome in Calgary Cardiovascular Outcome in Edmonton Cardiovascular Outcome in Ottawa Cardiovascular Outcome in Winnipeg Cardiovascular Outcome in Quebec City Cardiovascular Outcome in Hamilton Cardiovascular Outcome in Kitchener Cardiovascular Outcome in London Cardiovascular Outcome in Halifax Cardiovascular Outcome in New York Cardiovascular Outcome in Los Angeles Cardiovascular Outcome in Chicago Cardiovascular Outcome in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease